Abstract:c-Myc is an oncogene involved in many forms of cancer. Proteomic analysis of human P-493 B lymphoma cells and PC3 prostate cancer cells shows that c-Myc regulates the microRNAs miR-23a and miR-23b to increase the expression of the mitochondrial enzyme glutaminase. This leads to enhanced glutamine metabolism and contributes to the metabolic changes in Myc-driven cancers. This paper shows that c-Myc regulates the microRNAs miR-23a and miR-23b to increase the expression of the mitochondrial enzyme glutaminase. This leads to enhanced glutamine metabolism and contributes to the metabolic changes in c-Myc-driven cancers. Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen1,2. Notwithstanding the renewed interest in the Warburg effect, cancer cells also depend on continued mitochondrial function for metabolism, specifically glutaminolysis that catabolizes glutamine to generate ATP and lactate3. Glutamine, which is highly transported into proliferating cells4,5, is a major source of energy and nitrogen for biosynthesis, and a carbon substrate for anabolic processes in cancer cells, but the regulation of glutamine metabolism is not well understood1,6. Here we report that the c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs7,8 and stimulate cell proliferation9, transcriptionally represses miR-23a and miR-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells. This leads to upregulation of glutamine catabolism10. Glutaminase converts glutamine to glutamate, which is further catabolized through the tricarboxylic acid cycle for the production of ATP or serves as substrate for glutathione synthesis11. The unique means by which Myc regulates glutaminase uncovers a previously unsuspected link between Myc regulation of miRNAs, glutamine metabolism, and energy and reactive oxygen species homeostasis.

MYC sensitises cells to apoptosis by driving energetic demand

Ire1 Alpha Rnase-Dependent Lipid Homeostasis Promotes Survival In Myc-Transformed Cancers

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

MYC shapes ER-mitochondria calcium transfer by directly targeting : implications for MYC-induced safeguard mechanisms and cancer

Reprogramming Of Proline And Glutamine Metabolism Contributes To The Proliferative And Metabolic Responses Regulated By Oncogenic Transcription Factor C-Myc

Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation.

C-Myc Suppression of Mir-23A/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism.

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

Tumor Cell-Selective Regulation Of Noxa By C-Myc In Response To Proteasome Inhibition

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent

Transcriptional Activation of MYC-Induced Genes by GCN5 Promotes B-cell Lymphomagenesis

Myc Promotes Glutaminolysis in Human Neuroblastoma Through Direct Activation of Glutaminase 2

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma

Data from MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells

Identification of MYC synthetic lethal genes and networks

A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis

Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma